APOE and hyperlipidemia: Last, ApoE−/− and LDLr−/− mice do not respond well to lipid-lowering drugs used in the clinic [10, 11], making these models unsuitable in the development of novel therapeutic strategies against hyperlipidemia and vascular complications.